G. Steven Burrill
An introduction to Burrill Venture Capital
Flash required to view this video. Download the latest version here
G. Steven BurrillNews
Biotech outperforms market in May June 02, 2008 | Press Release
Biotech Treads Water in April May 01, 2008 | Press Release
Burrill Opens Registration for its 3rd Annual India Life Sciences Meeting April 25, 2008 | Press Release
See all News
Our Advisory Boards include some of the most respected professionals in the industry, including CEOs, Nobel laureates, and other industry luminaries.
- Burrill Life Sciences III Advisory Board
- Burrill Life Sciences II Advisory Board
- Burrill Biotechnology Advisory Board
- Burrill Agbio Advisory Board
- Burrill Nutraceuticals Advisory Board
Burrill Life Sciences III Advisory Board
Paul Berg—Cahill Professor in Biochemistry, Emeritus, Stanford University; Director, Emeritus, Beckman Center for Molecular and Genetic Medicine at Stanford; Nobel Laureate in Chemistry
Carl Feldbaum—President Emeritus, Biotechnology Industry Organization.
Frederick Frank—Vice Chairman and Director, Lehman Brothers.
Martin Gerstel—Chairman of Compugen, Keddem Bioscience and Evogene; Co-Chairman of Itamar Medical; former Co-Chairman and CEO of ALZA Corporation
Lee Hood—President of The Institute for Systems Biology
David M. Lawrence—Chairman and CEO (retired), Kaiser Foundation Health Plan and Hospitals
George Poste—CEO, Health Technology Networks; Director, The Biodesign Institute, Arizona State University; former CSTO and head of R&D, SmithKline Beecham
Tommy Thompson—Former Secretary of Health & Human Services; former Governor of Wisconsin; BLSCF II Advisory Board
Burrill Life Sciences II Advisory Board
Paul Berg—Cahill Professor in Biochemistry, Emeritus, Stanford University; Director,
Emeritus, Beckman Center for Molecular and Genetic Medicine at Stanford; Nobel Laureate
in Chemistry
Sean Carroll—Investigator, Howard Hughes Medical Institute; Professor of Genetics, University
of Wisconsin, Madison
Jonathan Dordick—The Howard P. Isermann Professor in the Departments of Chemical and
Biological Engineering and Biology, Center for Biotechnology and Interdisciplinary Studies,
Rensselaer Polytechnic Institute
Alain Enthoven—Marriner S. Eccles Professor of Public and Private Management Emeritus at
the Stanford Graduate School of Business
Frederick Frank—Vice Chairman and Director, Lehman Brothers
Paul Freiman—President and CEO of Neurobiological Technologies; former Chairman and
CEO, Syntex
Martin Gerstel—Chairman of Compugen, Keddem Bioscience, and Evogene; Co-Chairman
of Itamar Medical; former Co-Chairman and CEO of ALZA Corporation
Jeff Goldsmith—President, Health Futures
David M. Lawrence—Chairman and CEO (retired), Kaiser Foundation Health Plan and
Hospitals
Eric Lander—Director, Broad Institute of MIT and Harvard
Ernest Mario, Ph.D.—Chairman, CEO of Capnia, Palo Alto, California. Capnia is a privately
held pharmaceutical company utilizing carbon dioxide as a therapeutic medical gas to treat migraine
and rhinitus.
George Poste—CEO, Health Technology Networks; Director, The Biodesign Institute, Arizona
State University; former CSTO and head of R&D, SmithKline Beecham
L. John Wilkerson—Founder of the Wilkerson Group, now an IBM Company; Managing Director
of Galen Partners, a late-stage healthcare private equity fund
Keith R. Yamamoto—Professor of Cellular and Molecular Pharmacology, Executive Vice Dean
in the School of Medicine at the University of California, San Francisco (UCSF)
Burrill Biotechnology Advisory Board
Paul Berg—Cahill Professor in Biochemistry, Emeritus, Stanford University; Director, Emeritus, Beckman Center for Molecular and Genetic Medicine at Stanford; Nobel Laureate in Chemistry
Sean Carroll—Investigator, Howard Hughes Medical Institute; Professor of Genetics, University
of Wisconsin, Madison
Frederick Frank—Vice Chairman and Director, Lehman Brothers
Paul Freiman—President and CEO of Neurobiological Technologies; former Chairman and
CEO, Syntex
Martin Gerstel—Chairman of Compugen, Keddem Bioscience, and Evogene; Co-Chairman of Itamar Medical; former Co-Chairman and CEO of ALZA Corporation
Jeff Goldsmith—President, Health Futures
Eric Lander—Director, Broad Institute of MIT and Harvard
Ernest Mario, Ph.D.—Chairman, CEO of Capnia, Palo Alto, California. Capnia is a privately held pharmaceutical company utilizing carbon dioxide as a therapeutic medical gas to treat migraine and rhinitus.
George Poste—CEO, Health Technology Networks; Director, The Biodesign Institute, Arizona
State University; former CSTO and head of R&D, SmithKline Beecham
L. John Wilkerson—Founder of the Wilkerson Group, now an IBM Company and currently
Managing Director of Galen Partners, a late stage healthcare private equity fund
Keith R. Yamamoto—Professor of Cellular and Molecular Pharmacology, Executive Vice Dean
in the School of Medicine at the University of California, San Francisco (UCSF)
Burrill Agbio Advisory Board
Charles Arntzen—President and CEO Emeritus, Boyce Thompson Institute for Plant Research; Regent’s Professor, Arizona Biodesign Institute, Arizona State University; member of President George W. Bush’s Council of Advisors on Science and Technology (PCAST)
Dennis Purcell—Senior Managing Director, Aisling Capital and Perseus-Soros Management, LLC; former Managing Director of Life Sciences Investment Banking, Chase Hambrecht & Quist
Marc Zabeau—CEO Methexis Genomics; Scientific Advisor, Department of Plant Systems Biology, Flemish Interuniversity Institute for Biotechnology
Burrill Nutraceuticals Advisory Board
Charles Arntzen—President and CEO Emeritus, Boyce Thompson Institute for Plant Research; Regent’s Professor, Arizona Biodesign Institute, Arizona State University; member of President George W. Bush’s Council of Advisors on Science and Technology (PCAST)
Peter Barton Hutt—Senior Counsel, Covington & Burling, a Washington-based law firm
specializing in food and drug law; former Chief Counsel of the FDA; member of the Institute of
Medicine; teaches Food and Drug Law course at Harvard Law
Nancy Fogg-Johnson—Technology Commercialization Consultant, Technology and Business Ventures; Co-founder of Efficas and NutraGenomics; Former Vice President Biotechnology/ Food Ingredients R&D and Vice President Personal Care Drugs, Bayer; former Vice President, Basic Research, Campbell Soup; former Vice President, R&D and QA, Nabisco Grocery Company
Jordan Gutterman— Distinguished Professor of Medicine, University of Texas, M.D. Anderson
Cancer Center, Houston
Susan Kay Harlander—President, Biorational Consultants; Principal, BTSafety, LLC; former Vice President of Green Giant and Progresso R&D and Agricultural Research at The Pillsbury Company; former Vice President of Biotechnology Development, The Pillsbury Company
Peter Mattson—Founder and Chairman, MATTSON, Largest New Product Development Company in the US Food & Beverage Industry
Charles Muscoplat— Vice President for Statewide Strategic Resource Development; McKnight Presidential Leadership Endowed Chair; Professor of Medicine, Microbiology, Food Science, and Nutrition
